GlassScriptPhysician profile
Melinda S Walker
NPI 1306838156
$3,587.58
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $489 · 2021: $1,029 · 2022: $776 · 2023: $739 · 2024: $29.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $768.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $637.44 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $463.05 | 2019-2024 | Jardiance, Mounjaro |
| Novo Nordisk INC | $268.80 | 2020-2023 | Rybelsus, Ozempic |
| Amgen INC. | $239.38 | 2019-2023 | Prolia, Evenity, Repatha |
| Amarin Pharma, INC. | $216.17 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $193.90 | 2019-2023 | Spravato |
| Glaxosmithkline, LLC. | $172.80 | 2019-2023 | Shingrix, Arexvy |
| Acera Surgical, INC. | $149.19 | 2023 | Restrata Wound Matrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.04 | 2019-2023 | Ofev |
| Novartis Pharmaceuticals Corporation | $127.17 | 2019-2022 | |
| Dexcom, INC. | $89.27 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $88.58 | 2019-2022 | |
| Astellas Pharma US INC | $82.93 | 2019-2023 | Myrbetriq, Veozah |
| Eisai INC. | $81.46 | 2020 | |
| Sanofi-Aventis U.S. LLC | $79.93 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $79.04 | 2021-2022 | |
| Boston Scientific Corporation | $65.53 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.37 | 2022-2023 | |
| Vanda Pharmaceuticals INC. | $47.95 | 2020 | |
| Sanofi Pasteur INC. | $42.26 | 2019-2023 | |
| Esperion Therapeutics, INC. | $39.08 | 2021 | |
| Merck Sharp & Dohme LLC | $29.43 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.61 | 2022-2023 | Xifaxan |
| Pfizer INC. | $26.82 | 2019-2021 | |
| Abbott Laboratories | $25.47 | 2021-2022 | |
| Edwards Lifesciences Corporation | $20.10 | 2022 | |
| Almatica Pharma LLC | $18.75 | 2022 | |
| Avion Pharmaceuticals | $17.99 | 2021 | |
| Xeris Pharmaceuticals, INC. | $16.08 | 2023 | Gvoke Hypopen |
| Cranial Technologies, INC | $15.61 | 2023 | Doc Band |
| Jazz Pharmaceuticals INC. | $14.55 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melinda Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.